Nanomix Inc., (Nanomix), a leading nanotechnology company focused on development of next generation Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, today announced that is has closed private financing for approximately $12 million. The financing, received from a strategic corporate partner and existing investors, will fund the completion of development, registration clinical trials, and commercial launch of the Company's mobile diagnostic platform and initial assays.

About Nanomix Inc.

Nanomix's leadership in carbon nanotubes and nanoscale electronic sensors has enabled the development of the next generation of Point of Care testing systems where superior performance and rapid results can both be achieved in virtually any setting. The Nanomix mobile diagnostic platform, performs multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample. The compact size of the electronic instrument and credit card sized disposable test cartridge can be configured to run a wide variety of tests using various assay techniques.

Nanomix - Laboratory Performance at the Point of Care, visit: www.nano.com.